{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-225055","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2026-05-15T10:02:44+00:00","discovered_at":"2026-05-15T10:20:00.235906+00:00","generated_at":"2026-05-15T10:22:37.219882+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ARS Pharma reports Q1 revenue $22.7M, neffy net product revenue $17.5M","bullets":["Net loss $60.6M ($0.61/share); cash $201M; expects to fund to cash-flow break-even.","CVS Caremark formulary proposal in final stages; target July 1, 2026; gross-to-net target ~50%.","Sales force expanded to 148 reps; SG&A $72.2M includes DTC marketing investment.","Health Canada approved neffy on April 15; EU 1 mg dose approved for children 4+ years.","Phase 2b CSU trial interim population fully enrolled; data expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-225055","json":"https://secwatch.observer/filing/0001193125-26-225055.json","markdown":"https://secwatch.observer/filing/0001193125-26-225055.md","text":"https://secwatch.observer/filing/0001193125-26-225055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/0001193125-26-225055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/spry-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:22:37.219882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"832b4dff9cf98bd4bcc8a19bb2a18862e7bbd5c8","claim":"ARS Pharmaceuticals, Inc. reported first quarter of 2026 results: revenue $22.7 million, net income ($60.6 million), EPS ($0.61) per share basic and diluted.","evidence_excerpt":"ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 total revenue of $22.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/0001193125-26-225055-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Revenue","value":"$22.7 million"},{"label":"Net income","value":"($60.6 million)"},{"label":"EPS","value":"($0.61) per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}